Abstract

The implantation of pacemakers is an indispensable treatment for patients with bradycardia, with its usage increasing by nearly 20% in member countries of the European Society of Cardiology over the past decade. Traditional right ventricular pacing often leads to electromechanical dyssynchrony, which can contribute to the development and/or exacerbation of heart failure. Left bundle branch area pacing (LBBAP) is a novel treatment option, rapidly gaining popularity worldwide. It aims to provide more physiological cardiac stimulation through the left conduction pathways of the His bundle, with an aim of preventing the progression of heart failure. Although initial clinical studies have confirmed the efficacy and safety of this methodology,
larger-scale clinical trials are still ongoing. In Estonia, we commenced LBBAP implantations in March 2023, and within a year, this method has become an integral part of our daily clinical practice.